Interim data from a phase II study produced positive safety and efficacy data for bel-sar (belzupacap sarotalocan) for the first-line treatment of patients with early-stage choroidal melanoma. With an average of nine months of follow up, the interim data shows the evaluation of two key clinical endpoints: tumor control and visual acuity preservation using the suprachoroidal route of administration.
FDA approved Labcorp’s PGDx elio tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapies.
